Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

OncoArendi Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

POLAND Poland

Post An Enquiry

CPhI North America Online

Participation Not Confirmed

Update your events

OncoArendi and Galapagos Enter Into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Contact the Supplier

Lead Product(s): OATD-01

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Galapagos

Deal Size: $380.8 million Upfront Cash: $29.7 million

Deal Type: Licensing Agreement November 05, 2020

Details:

OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.